期刊
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS
卷 5, 期 3, 页码 222-224出版社
MEDKNOW PUBLICATIONS & MEDIA PVT LTD
DOI: 10.4103/0976-500X.136121
关键词
Delamanid; multidrug-resistant tuberculosis; mycolic acid inhibitor
Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据